Volume. 35, No. 2 july. 2011 - The Chest and Heart Association of ...
Volume. 35, No. 2 july. 2011 - The Chest and Heart Association of ...
Volume. 35, No. 2 july. 2011 - The Chest and Heart Association of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Chest</strong> & <strong>Heart</strong> Journal Vol. <strong>35</strong>, <strong>No</strong>.-2, July <strong>2011</strong>FDA Pregnancy Risk CategoryCategoryABCDXInterpretationControlled studies show no risk, Adequate, well-controlled studies in pregnant womenhave failed to demonstrate a risk to the fetus in any trimester <strong>of</strong> pregnancy<strong>No</strong> evidence <strong>of</strong> risk in humans. Adequate well-controlled studies in pregnant womenhave not shown increased risk <strong>of</strong> fetal abnormalities despite adverse findings in animals,orin the absence <strong>of</strong> adequate human studies ,animal studies show no fetal risk .<strong>The</strong> chance<strong>of</strong> fetal harm is remote,but remains a possibilities .Risk cannot be ruled out.Adequate well-controlled human studies are lacking <strong>and</strong> animalstudies have shown a risk to the fetus or are lacking as well there is a chance <strong>of</strong> fetalharm if the drug is administered during pregnancy but the potential benefits mayoutweigh the potential riskPositive evidence <strong>of</strong> risk .Studies in humans, or investigational or post marketing data,have demonstrated fetal risk.Nevertheless, potential benefits from the use <strong>of</strong> the drugmay outweigh the potential risk.Contraindicated in pregnancy . Studies in animals or humans or investigational or postmarketing reports have demonstrated positive evidence <strong>of</strong> fetal abnormalities or riskthat clearly outweighs any possible benefits to the patients .FDA Pregnancy risk category, TERIS rating <strong>of</strong> asthma medication 5Medication Risk Category TERIS rating(magnitude <strong>of</strong> teratogenic Risk/Quality,Quantity <strong>of</strong> Data)Salbutamol C Undetermined/LimitedLevo-salbutamol C NASameterol C Undetermined/Very LimitedBeclomethasone C Unlikely/Limited to FairBudesonide B Unlikely/Limited to FairFluticasone C NAMometasone C Undetermined/LimitedTriamcinolone C Undetermined/LimitedFluticasone/salmeterol C NAOral steroidCCromolyn B Unlikely/Fair to GoodNedocromil B Undetermined/Very LimitedMontelukast D Undetermined/Limit<strong>The</strong>ophylline C <strong>No</strong>ne/Fair to GoodSteps <strong>of</strong> Asthma <strong>The</strong>rapy during PregnancyStep Preferred Controller Medication Alternative Controller Medication1 <strong>No</strong>ne2 LDICS LTRA,theophylline,or cromolyn3 MDICS LDICS plus LABA,LTRAor theophylline4 MDICS plus LABA MDICS plus either LTRA or theophylline5 HDICS plus LABA6 HDICS plus LABA plus oral prednisolone110